Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic DisordersBusiness Wire • 10/11/23
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE TrialBusiness Wire • 09/19/23
Wall Street Analysts Believe Scholar Rock Holding Corporation (SRRK) Could Rally 264.53%: Here's is How to TradeZacks Investment Research • 09/07/23
Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business ProgressBusiness Wire • 08/09/23
New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular AtrophyBusiness Wire • 06/30/23
Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business ProgressBusiness Wire • 05/09/23
Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA ConferenceBusiness Wire • 05/08/23
Scholar Rock Announces the Addition of Richard Brudnick to Its Board of DirectorsBusiness Wire • 04/10/23
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business ProgressBusiness Wire • 03/07/23
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceBusiness Wire • 03/01/23
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 11/15/22
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business ProgressBusiness Wire • 11/14/22
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of EfficacyBusiness Wire • 11/10/22
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMABusiness Wire • 10/22/22
Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual MeetingBusiness Wire • 10/06/22